Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy
Who is this study for? Patients with Ovarian Cancer
What treatments are being studied? Cisplatin
Status: Recruiting
Location: See all (28) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• candidate for primary CRS
• histological or cytological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer
Locations
United States
California
City of Hope
RECRUITING
Duarte
New York
MSKCC New York
RECRUITING
New York
Other Locations
Denmark
Rigshospitalet Copenhagen
RECRUITING
Copenhagen
France
CHU de Besancon
RECRUITING
Besançon
Institut Bergonié
RECRUITING
Bordeaux
o Institut Bergonié, Bordeaux
RECRUITING
Bordeaux
CHU Lille
RECRUITING
Lille
Centre Leon Berard, Lyon
RECRUITING
Lyon
CHU Lyon
RECRUITING
Lyon
Institut du Cancer Montpellier
RECRUITING
Montpellier
Institut de Cancerologie de l'Ouest, ICO Nantes)
RECRUITING
Nantes
Institut Curie Paris
RECRUITING
Paris
CHRU Strasbourg
RECRUITING
Strasbourg
Oncopole, Institute Universitaire du Cancer de Toulouse (IUCT Toulouse)
RECRUITING
Toulouse
Ireland
Mater Misericordiae University Hospital, Dublin
RECRUITING
Dublin
Italy
Policlinico Sant'Orsola, Bologna
RECRUITING
Bologna
Fondazione Policlinico A Gemelli IRCCS
RECRUITING
Roma
Netherlands
Amsterdam UMC
RECRUITING
Amsterdam
Antoni van leeuwenhoek
RECRUITING
Amsterdam
Catharina Hospital
RECRUITING
Eindhoven
Medisch Spectrum Twente
RECRUITING
Enschede
UMCG
RECRUITING
Groningen
Leiden University Medical Center (LUMC)
RECRUITING
Leiden
Maastricht UMC+
RECRUITING
Maastricht
Radboud MC
RECRUITING
Nijmegen
Erasmus MC
RECRUITING
Rotterdam
UMCU
RECRUITING
Utrecht
Sweden
Alice Bjoernlund-Larsen
RECRUITING
Uppsala
Contact Information
Primary
Willemien van Driel, MD, PhD
OVHIPEC@nki.nl
031 20 512 7918
Backup
Lot Aronson
OVHIPEC@nki.nl
031 20 512 7918
Time Frame
Start Date: 2020-01-01
Estimated Completion Date: 2026-04-01
Participants
Target number of participants: 538
Treatments
No_intervention: conventional surgery
Primary cytoreductive surgery without HIPEC
Experimental: HIPEC
Primary cytoreductive surgery with HIPEC with cisplatin
Related Therapeutic Areas
Sponsors
Leads: The Netherlands Cancer Institute